| Dr Erika Mae Reyes, OD | |
|
490 Illinois Street, San Francisco, CA 94143 | |
| (415) 353-2800 | |
| (415) 353-2654 |
| Full Name | Dr Erika Mae Reyes |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 9 Years |
| Location | 490 Illinois Street, San Francisco, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043695646 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 15387 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ucsf Medical Center | San francisco, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ucsf Medical Group Business Services | 3779497870 | 1064 |
News Archive
In advance of scheduled investor meetings and the Company's participation at an industry conference, Tenet Healthcare Corporation today refined its 2011 Outlook for Adjusted EBITDA.
"United Nations officials [on Tuesday] welcomed Pope Francis' public commitment to support those who live in poverty and suffer from hunger, and expressed their readiness to work with the new leader of the Catholic Church on these issues," the U.N. News Centre reports (3/19).
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.
› Verified 3 days ago
| Provider Name | University Of California San Francisco |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
In advance of scheduled investor meetings and the Company's participation at an industry conference, Tenet Healthcare Corporation today refined its 2011 Outlook for Adjusted EBITDA.
"United Nations officials [on Tuesday] welcomed Pope Francis' public commitment to support those who live in poverty and suffer from hunger, and expressed their readiness to work with the new leader of the Catholic Church on these issues," the U.N. News Centre reports (3/19).
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.
› Verified 3 days ago
| Provider Name | Ucsf Medical Group Business Services |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
In advance of scheduled investor meetings and the Company's participation at an industry conference, Tenet Healthcare Corporation today refined its 2011 Outlook for Adjusted EBITDA.
"United Nations officials [on Tuesday] welcomed Pope Francis' public commitment to support those who live in poverty and suffer from hunger, and expressed their readiness to work with the new leader of the Catholic Church on these issues," the U.N. News Centre reports (3/19).
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.
› Verified 3 days ago
| Provider Name | Golden Gate Optometry Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1821058389 PECOS PAC ID: 7315943891 Enrollment ID: O20061005000289 |
News Archive
In advance of scheduled investor meetings and the Company's participation at an industry conference, Tenet Healthcare Corporation today refined its 2011 Outlook for Adjusted EBITDA.
"United Nations officials [on Tuesday] welcomed Pope Francis' public commitment to support those who live in poverty and suffer from hunger, and expressed their readiness to work with the new leader of the Catholic Church on these issues," the U.N. News Centre reports (3/19).
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.
› Verified 3 days ago
| Provider Name | Kim L Cooper Md A Professional Corporation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1881851566 PECOS PAC ID: 6709940406 Enrollment ID: O20090603000691 |
News Archive
In advance of scheduled investor meetings and the Company's participation at an industry conference, Tenet Healthcare Corporation today refined its 2011 Outlook for Adjusted EBITDA.
"United Nations officials [on Tuesday] welcomed Pope Francis' public commitment to support those who live in poverty and suffer from hunger, and expressed their readiness to work with the new leader of the Catholic Church on these issues," the U.N. News Centre reports (3/19).
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erika Mae Reyes, OD 490 Illinois Street, San Francisco, CA 94143 Ph: (415) 353-2800 | Dr Erika Mae Reyes, OD 490 Illinois Street, San Francisco, CA 94143 Ph: (415) 353-2800 |
News Archive
In advance of scheduled investor meetings and the Company's participation at an industry conference, Tenet Healthcare Corporation today refined its 2011 Outlook for Adjusted EBITDA.
"United Nations officials [on Tuesday] welcomed Pope Francis' public commitment to support those who live in poverty and suffer from hunger, and expressed their readiness to work with the new leader of the Catholic Church on these issues," the U.N. News Centre reports (3/19).
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.
› Verified 3 days ago
Daniel Situ, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 100 Battery St, San Francisco, CA 94111 Phone: 415-399-1573 | |
Jennifer Elizabeth Ding, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2007 Irving St, San Francisco, CA 94122 Phone: 415-564-1818 | |
Opt Optometric Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1415 Valencia St, San Francisco, CA 94110 Phone: 415-572-5500 | |
Geri Cheng, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 3518 Balboa St, San Francisco, CA 94121 Phone: 415-386-3937 | |
Bruce Gary Dong, OPTOMETRIST Optometrist Medicare: Not Enrolled in Medicare Practice Location: 619 Irving St, San Francisco, CA 94122 Phone: 415-661-8253 Fax: 415-661-2490 | |
Philip Tawil, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2049 Oak St Apt 1, San Francisco, CA 94117 Phone: 415-431-2988 | |
Leona Landers, O.d. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 101 Howard St, Suite B, San Francisco, CA 94105 Phone: 415-908-2733 |